WO2013039428A3 - Dérivés de quinoléine et notamment 1-(2-chloroquinoléin-3-yl)-4-diméthylamino-2-(naphthalén-1-yl)-1-phénylbutan-2-ols 5,6,7- substitués, procédés de leur production et d'utilisation - Google Patents

Dérivés de quinoléine et notamment 1-(2-chloroquinoléin-3-yl)-4-diméthylamino-2-(naphthalén-1-yl)-1-phénylbutan-2-ols 5,6,7- substitués, procédés de leur production et d'utilisation Download PDF

Info

Publication number
WO2013039428A3
WO2013039428A3 PCT/RU2012/000725 RU2012000725W WO2013039428A3 WO 2013039428 A3 WO2013039428 A3 WO 2013039428A3 RU 2012000725 W RU2012000725 W RU 2012000725W WO 2013039428 A3 WO2013039428 A3 WO 2013039428A3
Authority
WO
WIPO (PCT)
Prior art keywords
methoxy
producing
quinoline derivatives
phenylbutan
chloroquinolin
Prior art date
Application number
PCT/RU2012/000725
Other languages
English (en)
Russian (ru)
Other versions
WO2013039428A2 (fr
Inventor
Анна Борисовна НАЗАРЕНКО
Владимир Егорович ФЕДОРОВ
Вадим Егоревич ИЛЬИН
Антон Владимирович ОМЕЛЬКОВ
Евсей Александрович РУЧКО
Original Assignee
Закрытое Акционерное Общество "Фарм-Синтез"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Закрытое Акционерное Общество "Фарм-Синтез" filed Critical Закрытое Акционерное Общество "Фарм-Синтез"
Publication of WO2013039428A2 publication Critical patent/WO2013039428A2/fr
Publication of WO2013039428A3 publication Critical patent/WO2013039428A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux dérivés de quinoléines tels que les 1-(2-chloroquinoléin-3-yl)-4-diméthylamino-2-(naphthalén-1-yl)-1-phénylbutan-2-ols substitués, un procédé de leur fabrication et aussi leur utilisation en tant que agents antimycobactériens, notamment des 1-(2-chloroquinoléin-3-yl)-4-diméthylamino-2-(naphthalén-1-yl)-1-phénylbutan-2-ols 5,6,7-substitués de la formule générale (I), dans laquelle R1 est Н ou méthoxy, R2 est Н, méthoxy ou -O-(CH2)n-O-, R3 est Н, méthoxy ou -O-(CH2)n-O-, n=1-2, et aussi leurs sels pharmaceutiquement acceptables avec des acides manifestant une activité par rapport aux mycobactéries. L'invention concerne aussi un procédé de fabrication des compositions de la formule (I) qui consiste en l'interaction des arylchinolines correspondantes avec un cétone aromatique et leur utilisation en tant que principe actif dans la création de préparations médicamenteuses dirigées contre la tuberculose.
PCT/RU2012/000725 2011-09-12 2012-09-04 Dérivés de quinoléine et notamment 1-(2-chloroquinoléin-3-yl)-4-diméthylamino-2-(naphthalén-1-yl)-1-phénylbutan-2-ols 5,6,7- substitués, procédés de leur production et d'utilisation WO2013039428A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2011137490 2011-09-12
RU2011137490/04A RU2486175C2 (ru) 2011-09-12 2011-09-12 Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений

Publications (2)

Publication Number Publication Date
WO2013039428A2 WO2013039428A2 (fr) 2013-03-21
WO2013039428A3 true WO2013039428A3 (fr) 2013-05-10

Family

ID=47883906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2012/000725 WO2013039428A2 (fr) 2011-09-12 2012-09-04 Dérivés de quinoléine et notamment 1-(2-chloroquinoléin-3-yl)-4-diméthylamino-2-(naphthalén-1-yl)-1-phénylbutan-2-ols 5,6,7- substitués, procédés de leur production et d'utilisation

Country Status (2)

Country Link
RU (1) RU2486175C2 (fr)
WO (1) WO2013039428A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (fr) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Derives de quinoleine et leur utilisation en tant qu'inhibiteurs mycobacteriens
WO2006125769A1 (fr) * 2005-05-25 2006-11-30 Janssen Pharmaceutica N.V. Procede de preparation de (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphtalenyl-beta-phenyl-3-quinoline-ethanol
RU2006145336A (ru) * 2004-05-21 2008-06-27 Чирон Корпорейшн (Us) Замещенные производные хинолина, как ингибиторы митотического кинезина
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2321A (en) * 2004-01-29 2011-11-16 Janssen Pharmaceutica Nv Quinoline derivatives for use as mycobactrial inhibitor.
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (fr) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Derives de quinoleine et leur utilisation en tant qu'inhibiteurs mycobacteriens
RU2006145336A (ru) * 2004-05-21 2008-06-27 Чирон Корпорейшн (Us) Замещенные производные хинолина, как ингибиторы митотического кинезина
WO2006125769A1 (fr) * 2005-05-25 2006-11-30 Janssen Pharmaceutica N.V. Procede de preparation de (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphtalenyl-beta-phenyl-3-quinoline-ethanol
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе

Also Published As

Publication number Publication date
RU2011137490A (ru) 2013-03-20
RU2486175C2 (ru) 2013-06-27
WO2013039428A2 (fr) 2013-03-21

Similar Documents

Publication Publication Date Title
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
MX2021008356A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
EA201491671A1 (ru) Гетероциклильные соединения
BR112018069302A2 (pt) naftiridinas como antagonistas de integrina
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
BR112014027181A2 (pt) derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1
NZ627274A (en) Anesthetic compounds and related methods of use
BR112015016001A2 (pt) compostos, composições farmacêuticas e respectivos usos e método para tratar ou prevenir infecção bacteriana
MX338707B (es) Compuestos heterociclicos activadores de proteina cinasa activada por 5'-amp (ampk) y metodos para emplearlos.
MX2015009950A (es) Compuestos de imidazopiridina y sus usos.
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
WO2012116290A3 (fr) Stéroïdes neuroactifs substitués par 17(20)-z-vinylcyano, promédicaments de ceux-ci et procédés de traitement les utilisant
AU2011274192A8 (en) Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
UY32816A (es) Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
BR112013019160A2 (pt) novos compostos, composição farmacêutica, uso, processos e métodos
WO2014062838A3 (fr) Modulateurs de pkm2 et procédés pour les utiliser
AR094122A1 (es) Compuestos triciclicos moduladores de la actividad de cftr
PH12015500012B1 (en) Benzodioxole derivative and preparation method and use thereof
IN2015DN00837A (fr)
CO6592109A2 (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida
BR112014029838A2 (pt) formas no estado sólido de n-((s)-2,3-di-hidróxi-propil)-3-(2-flúor-4-iodo-fenilamino)- isonicotinamida
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12831763

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12831763

Country of ref document: EP

Kind code of ref document: A2